Related Posts:
April 28, 2026
Abbott has received FDA clearance and CE Mark for its new AI-powered Ultreon™ 3.0 coronary imaging system aimed at improving physician decision-making during complex heart artery procedures through advanced optical coherence tomography technology.
Read more →April 25, 2026
Abbott unveiled new clinical trial results during Heart Rhythm Society 2026 showing positive outcomes across several devices targeting abnormal heart rhythms. Highlights include strong safety profiles and successful treatment rates using advanced technologies such as pulsed field ablation catheters and conduction system pacing leads.
Read more →April 22, 2026
Abbott has shared new data on its Cancerguard multi-cancer early detection test at AACR's annual meeting. The company highlighted improved performance using multiple biomarker classes and received recognition for long-term research outcomes supporting clinical impact.
Read more →
Sign-up for the Weekly Newsletter from Prairie State Wire.